An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.
This clinical trial is testing an experimental medication called zipalertinib to see how well it works and how safe it is for people with a specific type of advanced lung cancer. It is designed to help researchers find better treatment options for patients whose cancer has a specific genetic change known as an EGFR exon 20 insertion mutation.
You may be able to join if you are 18 or older and have been diagnosed with advanced lung cancer that has this specific genetic change confirmed by a lab test. However, you cannot take part if you have previously used zipalertinib, are in another clinical trial, or recently received certain types of radiation or immunotherapy.
Participants will receive the study drug zipalertinib and may also be given medication cocktails to help researchers understand how your body processes the drug. Your health and safety will be carefully monitored by the medical team throughout the study.
This study is currently recruiting participants at multiple locations, including sites in Alabama, California, and Massachusetts in the United States.
- 1Tests the experimental cancer drug zipalertinib
- 2For adults with advanced lung cancer and a specific genetic mutation
- 3Currently actively recruiting patients at multiple medical centers
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.